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Abstract
Despite recent controversies about toxicity and reduced efficacy, vancomycin remains the current treatment of choice for
methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia. The parameter associated with treatment success is the vancomycin 24-h
area under concentration-time curve to MIC ratio (AUC0–24/MIC). We aimed to determine the utility of calculated AUCs and explore the
optimal AUC0–24/MIC targets associated with treatment success. In this single-centre retrospective observational cohort study of 127
patients with MRSA bacteraemia, forty-five (35.4%) did not respond to vancomycin treatment. Patient characteristics were essentially the
same between those who did not respond to vancomycin treatment and those with treatment success, with independent predictors of
treatment failure being source of bacteraemia (odds ratio (OR), 4.29; 95% confidence interval (CI), 1.50–12.26; p 0.007) and not achieving
an AUC0–24/MICBMD (using broth microdilution) target of ≥398 (OR, 11.4; 95% CI, 4.57–28.46; p< 0.001). Bacteraemic source-specific
thresholds were observed with a higher AUC0–24/MICBMD target of 440 required for high-risk sources (e.g. infective endocarditis)
compared with 330 for low-risk sources (line related bacteraemia). Overall treatment success in patients with MRSA bacteraemia was
associated with a vancomycin AUC0–24/MICBMD target of ≥398, with source-specific targets observed. Future vancomycin practice
guidelines will need to take into account MIC methodology, source of bacteraemia and patient populations prior to setting targets and
monitoring recommendations.
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Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia
accounts for a high proportion of healthcare and community
onset infections worldwide. These bacteraemic episodes in
turn result in significant patient morbidity and mortality [1–3].
The mainstay of therapy remains vancomycin despite contro-
versies about efficacy and potential toxicity [4]. Glycopeptides
including vancomycin exhibit concentration-independent kill-
ing, with the pharmacodynamic parameter best associated with
efficacy being the ratio of the 24-h area under the concentra-
tion-time curve to minimum inhibitory concentration
(AUC0–24/MIC) [5,6]. Using broth microdilution (BMD), initial
AUC0–24/MIC thresholds of 866 and 345 for bacterial erad-
ication and clinical success, respectively, were observed
following an S. aureus pneumonia study [7]. In light of these
results and animal infection model data consensus guidelines
recommended a vancomycin AUC0–24/MIC target of ≥400 for
serious MRSA infections [8]. Subsequently, similar targets using
classification regression tree (CART) analysis have been
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observed in MRSA bacteraemia studies [9–12]. Although slight
differences in the targets exist this is largely explained by the
MIC methodology employed, with AUC0–24/MICEtest targets
between 214 and 293 [9–11] compared with AUC0–24/MICBMD
targets between 373 and 421 [11,12].
Notwithstanding these vancomycin exposure targets, guide-
lines published in 2009 continue to recommend monitoring of
steady state trough concentrations and suggest aiming for levels
between 15 and 20 mg/L for serious infections [8]. This
recommendation was partly based on modelling, which showed
appropriate target attainment provided isolates had MICs
≤1 mg/L and the availability of trough measurements in routine
diagnostic laboratories [7,13,14]. Consequently, to assist
clinicians in achieving recommended vancomycin troughs,
several nomograms have been validated and published [15].
Two recent controversies, however, have challenged
vancomycin dosing based on trough concentrations. On the
one hand, increased mortality and treatment failures are
observed with high vancomycin MIC MRSA infections [4,16].
On the other hand, more aggressive dosing leads to a greater
chance of renal injury [17]. Both these concerns argue for
dosing aimed at PK/PD targets, which would optimize
individual patient exposure and at the same time minimize
renal injury. Several methods exist for determining vancomycin
AUCs. These include deriving vancomycin AUC from validated
formulae, population models or Bayesian estimations.
Although each has its own advantages and disadvantages, the
latter two methods currently are unlikely to become routine,
as they require appropriate infrastructure, frequent sampling
and highly skilled staff to be implemented [18].
We undertook this study to evaluate the utility of
previously validated AUC predictions (based on creatinine
clearance estimation) and explore the optimal AUC0–24/MIC
targets for vancomycin in patients with MRSA bacteraemia and
whether observed targets are influenced by sources of
bacteraemia.
Methods
Study population
Following institutional ethics approval, all adult patients
(>18 years) admitted with MRSA bacteraemia to Liverpool
Hospital between January 2006 and January 2012 were
screened for inclusion in this retrospective observational
cohort study. Patients were included if they met the following
criteria: they received ≥7 days of vancomycin monotherapy
following MRSA bacteraemia diagnosis and had an actual
weight recorded in the medical record. Patients with chronic
renal impairment requiring dialysis prior to admission were
excluded from the study, as clearance calculations are less
robust in these patients. In patients with multiple MRSA
bacteraemic episodes over the period only the first episode
was included in the study.
Data collection
Data for age, sex, source of bacteraemia and weight were
collected following a detailed review of the medical records.
Similarly, all co-morbidities were collated and used to calculate
the Charlson weighted index for each individual patient. The
APACHE II score was used as a marker of illness severity and
was calculated based on the worst physiological parameters
within the first 48 h following the positive MRSA blood culture
bottle [19]. Administered vancomycin doses, including loading
doses if prescribed, for each patient were confirmed using our
pharmacy-dispensing database. Vancomycin troughs (obtained
a minimum of 12 h after the last dose) were obtained from the
biochemistry data and correlated with date and timing of
vancomycin to ensure steady state trough concentration.
Microbiology
In all patients, including patients with persistent bacteraemia,
only the first positive blood culture isolate was used for MIC
determination. All isolates were retrieved from 80°C
storage and subcultured on horse blood agar (HBA) twice
prior to testing. Etest (0.016–256 mg/L; AB bioMerieux, Solna,
Sweden) vancomycin MICs were determined according to the
manufacturer’s instructions. In addition, broth microdilution
(BMD) was performed on all isolates as per the Clinical and
Laboratory Standard Institute (CLSI) methodology [20], inclu-
sive of an additional 1.5 mg/L concentration step. Heterore-
sistant vancomycin intermediate S. aureus (hVISA) testing was
not performed.
Vancomycin pharmacokinetic/pharmacodynamic data
Vancomycin AUC was calculated using a validated formula [7]
based on previously established vancomycin pharmacokinetics
[21], where the estimated AUC equals the total vancomycin
dose in mg over 24 h/([(creatinine clearance 9 0.79) +
15.4] 9 0.06). As in the original study, creatinine clearance
(CLCR) was estimated using the Cockcroft-Gault equation; that
is, CLCR = {[(140  age in years) 9 recorded actual body
weight in kg]/(serum creatinine in lM 9 0.814)} or 9 0.85 if
female [22]. For overweight patients (weight >100 kg)
adjusted body weight (which equates to ideal body
weight + 0.4 9 (actual  ideal body weight)) was used to
calculate the CLCR. AUCs were calculated using the total
vancomycin dose, which corresponded with dosing at steady
state conditions (between 72 and 96 h). Calculations were not
dependant on subsequent clinician-directed dosage changes
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based on obtained trough levels. Both MIC methodology
results were used to examine AUC0–24/MIC targets.
Definitions
The source of bloodstream infections (BSIs) was classified as
previously described [23] into three categories: low-risk
sources (related mortality <10%), which included intravenous
catheter, urinary tract, ear-nose-larynx and gynaecological
sources; intermediate-risk sources (associated mortality
between 10 and 20%), which included osteo-articular sources,
soft tissue and unknown sources; and high-risk sources
(associated mortality >20%), which included endovascular
sources, pneumonia, abdominal sources and central nervous
system foci.
Outcomes
Similarly to previous studies a composite endpoint comprising
all current aspects considered as treatment failure was chosen
[12,24]. Following chart review by the authors, vancomycin
treatment failure was defined as any one of the following: (i)
30-day overall mortality; (ii) persistent bacteraemia ≥7 days; or
(iii) microbiological failure (i.e. MRSA isolation from a sterile
site) with persistent signs and symptoms of MRSA infection
following 14 days of vancomycin [12,24].
Statistical analysis
Categorical variables were compared using the v2 test or
Fishers exact test, and continuous variables compared by the
Students t-test or Mann–Whitney U-test Classification and
Regression Tree (CART) analysis (which uses decision tree
algorithms to determine the best if-then split conditions that
accurately predict an outcome of interest) was used to identify
overall and source-specific AUC/MIC targets for treatment
failure. A p value of <0.05 was considered significant. Multivar-
iable backward stepwise logistic regression analysis was
performed to identify predictors of treatment failure. All
variables with a p value <0.2 and those previously identified to
be associated with outcome (e.g. elevated vancomycin MICE test,
APACHE II score and CWI) were included in the model a priori
with the goodness of fit of the final model assessed using the
Hosmer-Lemeshow statistic. All calculations were computed
using SPSS (version 22.0) and CART software (Salford Predic-
tive Modeler version 7; Salford Systems, San Diego, CA, USA).
Results
Demographics
During the study period 199 MRSA episodes were identified.
Of these, 127 patients were included in the study, with patients
excluded for the following reasons: missing clinical data
(n = 9); chronic renal impairment requiring dialysis (n = 27);
no stored isolate (n = 2); not treated, treated with combina-
tion or alternative therapy (n = 32); and recurrent episodes
(n = 2).
The median age was 64.6 years (range 22–95) and there
was a predominance of male patients (68.5%). All patients had
at least two co-morbidities with a median APACHE II score of
11 (range 0–37). The majority of episodes occurred in hospital
(52.0%), with line-related bacteraemia being the most common
source (26.7%) of bacteraemia. Infective endocarditis (n = 12),
pneumonia (n = 19), abdominal sources (n = 6) and
non-endocarditis vascular sources (n = 2) made up all high-risk
episodes and together accounted for 30.7% of all episodes.
Susceptibility testing
The isolates’ MIC distribution by methodology is displayed in
Table 1, with a significant difference observed between Etest
results (MIC90 = 2 mg/L) and broth microdilution
(MIC90 = 1 mg/L) (Spearman’s rho = 0.398; p< 0.01).
Vancomycin trough levels
The median intravenous vancomycin dose at steady state was
2000 mg/day (range 500–4000 mg/day) administered over 2–
4 h, which resulted in a median trough level of 13.1 mg/L
(range 3.5–35.7 mg/L) based on a single patient’s result taken
at steady state. Depending on bacteraemia source, patients
were treated with intravenous therapy for between 2 and
6 weeks; no combination therapy was prescribed in any
episodes. Oral step-down therapy with rifampicin and fusidic
acid was employed predominantly in patients with bone and
joint infections and only occurred following completion of
intravenous antibiotics.
Renal clearance and vancomycin AUC0–24
The median weight was 70 kg (range 39–184 kg), with 9.4%
(12/127) of patients weighing greater than 100 kg. Renal
function was impaired at baseline secondary to the bactera-
emia in 34.4% (44/128), with a median calculated creatinine
TABLE 1. Vancomycin inhibitory concentration testing
results by methodology
Etest MIC (mg/L)
No of isolates with BMD MIC (mg/L)
Total0.25 0.5 1 1.5 2 4
0.5 1 5 4 0 0 0 10
0.75 0 10 14 0 0 0 24
1 0 6 32 2 2 0 42
1.5 0 2 34 1 0 1 38
2 0 0 9 2 2 0 13
Total 1 23 93 5 4 1 127
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clearance (Cockcroft-Gault equation) of 67. mL/min (range
11–191 mL/min). Only one patient had a supranormal
(>130 mL/min) calculated creatinine clearance and not sur-
prisingly this patient attained an AUC0–24/MICBMD <400. The
patient’s MRSA bacteraemia was secondary to a line-related
source with subsequent treatment failure (exit site abscess
21 days after commencement of vancomycin and line
removal). None of our presented results changed when this
patient was excluded.
A median calculated vancomycin AUC0–24/MIC ratio of
448 mg*h/L (range 72–1906 mg*h/L) using BMD MIC results
was obtained. Given the 1–2 dilution higher Etest MIC results
compared with BMD, not surprisingly, the median vancomycin
AUC0–24/MIC ratiowas significantly lower at 369 mg*h/L (range
88–1341 mg*h/L) when calculated using Etest results (p< 0.01).
Calculated AUC values (Spearman’s rho = 0.756) corre-
lated better with AUC0–24/MICBMD values compared with
vancomycin trough levels at 96 h (Spearman’s rho = 0.301).
Of patients achieving an appropriate AUC0–24/MICBMD target
of ≥400, 61% (47/77) had vancomycin troughs <15 mg/L and
thus potentially would have their dosing increased, resulting in
a possible increased risk of nephrotoxicity. Similarly, 34% (17/
50) had trough levels between 15 and 20 mg/L but did not
achieve the recommended target, resulting in ‘under’-expo-
sure (See Fig. 1).
Effect of AUC/MIC attainment on treatment failure
Forty-five patients (35.4%) had evidence of treatment failure:
persistent bacteraemia (n = 11), microbiological failure
(n = 12) and overall 30-day mortality (n = 22). Seven patients
met more than one category for treatment failure (See
Table 2). Diagnosis of persistent bacteraemia occurred on
average 12 and 10 days following the initial positive blood
culture bottle and initiation of vancomycin. Microbiological
failure was confirmed on average 20 days from the initiation of
treatment and occurred predominantly (66.7%; 8/12) in
patients who did not undergo definitive source control (e.g.
device removal or abscess drainage). Not surprisingly, given
the definitions, source of bacteraemia (i.e. high vs. intermedi-
ate/low risk sources) predicted overall 30-day mortality
(p< 0.001) and persistent bacteraemia (p 0.044) but not
microbiological failure (p 0.590) (Table 2).
Using CART, a significant AUC0–24/MICBMD of 398 was
detected: vancomycin failure occurred in 54% (27/50) of
patients with AUC0–24/MIC less than 398 compared with
23.4% (18/77) in patients with values greater or equal to 398
(p< 0.01). Similar results were seen with AUC0–24/MICEtest but
at a lower target of 270 (data not shown). Other variables
associated with treatment failure included presence of chronic
lung disease, receipt of immunosuppression at time of
bacteraemia and high-risk sources (see Table 3). Although an
elevated MIC by Etest was associated with higher rates of
failure it did not reach statistical significance (p 0.137).
Independent predictors of treatment failure based on multi-
variable logistic regression (Table 4) included vancomycinAUC0–
24/MICBMD <398, high-risk bacteraemic sources and immuno-
suppression (Hosmer-Lemeshow statistic for the final model,
chi-squared 1.2, p 0.882). AUC0–24/MICEtest<270was likewise an
independent predictor of failure when included in the model in
place of AUC0–24/MICBMD (OR, 5.4; 95%CI, 2.0–14.7; p< 0.001).
FIG. 1. Scatterplot of measured vanco-
mycin trough levels at steady state and
vancomycin AUC0–24/MICBMD. Lines
represent recommended vancomycin
trough targets on the x-axis and
vancomycin AUC0–24/MICBMD on the
y-axis.
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Effect of bacteraemic source on AUC/MIC target
Source-specific AUC0–24/MICBMD targets were identified using
CART analysis: 440, 363 and 330 for high, intermediate and
low-risk sources, respectively. The relationship between
AUC0–24/MICBMD values and treatment failure stratified by
source of bacteraemia can be seen in Fig. 2. Patients achieving
AUC0–24/MICBMD values below identified targets were signif-
icantly more likely to experience treatment failures compared
with patients achieving levels above the target (Fig. 3). The
difference between AUC0–24/MICBMD targets for intermediate
and low risk sources, although small, was meaningful. When
applying the lower target of 330 to intermediate sources, two
less treatment failures (2/11; 18%) were identified. Specific
bacteraemic diagnoses were not examined due to the low
numbers of patients in each of the groups.
Discussion
There are several notable findings from our observational
cohort study. First, vancomycin steady state trough
concentrations correlated poorly with pharmacodynamic tar-
gets. This is not surprising as the denominator of the AUC0–24/
MICBMD equation has an exponential effect on the final result.
Moreover, dosing adjustments based on vancomycin trough
concentrations would have resulted in a considerable propor-
tion of patients attaining AUC0–24/MICBMD above or below
recommended targets. Consequences of not attaining recom-
mended targets include the possible emergence of vancomycin
hetero-resistance with under-dosing [25] and increased risk of
nephrotoxicity with increasing drug exposure [26]. Therefore,
to optimize individual patient vancomycin exposure requires
AUC0–24/MICBMD monitoring. However, as opposed to vanco-
mycin trough monitoring, AUC0–24/MICBMD monitoring is
more complex and relies on appropriate available expertise.
Nevertheless, our data confirm the utility of using a pub-
lished formula for AUC estimation as we observed a similar
AUC0–24/MICBMD target (of ≥398) associated with treatment
success [9–12]. Second, required AUC0–24/MIC targets are
influenced by the source of bacteraemia, with higher targets
required for treatment success in high-risk sources such as
infective endocarditis compared with low-risk sources such as
line-related bacteraemia.
Vancomycin treatment failure was predominantly observed
in patients with high-risk bacteraemic sources. This
TABLE 2. Breakdown of treatment failure by prognostic
source of bacteraemia
Characteristic Number of events
Overall 30-day mortality 22
High-risk sources (n = 39) 16a
Intermediate sources (n = 50) 4
Low-risk sources (n = 38) 3
Persistent bacteraemia 11
High-risk sources (n = 39) 5 (5)bc
Intermediate sources (n = 50) 2 (2)c
Low-risk sources (n = 38) 4
Microbiological failure 12
High-risk sources (n = 39) 4d
Intermediate sources (n = 50) 6
Low-risk sources (n = 38) 2
Source of bacteraemia grouped into one of three groups based on overall
mortality risk (see text for details).
Low risk: line-related bacteraemia (n = 35) and other sources (n = 3).
Intermediate risk: bone and joint (n = 14), skin and soft tissue infections (n = 20),
deep abscess (n = 4), no identified focus (n = 12).
High risk: infective endocarditis (n = 12), pneumonia (n = 19), abdominal sources
(n = 6) and non-endocarditis vascular sources (n = 2).
aHigh-risk sources were significantly more likely to result in overall mortality
compared with intermediate/low-risk sources (p< 0.001).
bHigh-risk sources were significantly more likely to result in persistent bacter-
aemia compared with intermediate/low-risk sources (p 0.044).
cNumbers in the brackets represent additional patients who had persistent
bacteraemia. These seven patients all died and thus were included in the analysis as
a death only. No patients with microbiological failure died at 30 days or had
persistent bacteraemia.
dSimilar rates of microbiological failure were seen irrespective of source of
bacteraemia (p 0.590).
TABLE 3. Patient demographics grouped by treatment out-
comea
Characteristic
Treatment
failure (n = 45)
Treatment
success
(n = 82) p Value
Age ≥70 years 20 (44.4) 34 (41.5) 0.851
Male sex 29 (64.4) 58 (70.7) 0.550
Median weight in kg
(range)
70 (40–110) 70 (39–184) 0.721
Co-morbidities
Heart disease 10 (22.2) 18 (22.0) 0.972
Diabetes 14 (31.1) 28 (34.1) 0.844
Malignancy 15 (33.3) 21 (25.6) 0.624
Chronic liver disease 3 (6.7) 6 (7.3) 1.000
Chronic lung disease 9 (20.0) 6 (7.3) 0.034
Immunosupression 11 (24.4) 10 (12.2) 0.076
Charlson weighted index
≥3
19 (42.2) 34 (41.5) 0.934
Origin of bacteraemia
Community onset 24 (53.3) 37 (45.1) 0.320
Hospital onset 21 (46.7) 45 (54.9)
Location of bacteraemia
Transit to or in ICU 14 (31.1) 19 (23.2) 0.577
Ward patient 31 (68.9) 63 (76.8)
Severity of illness
Median APACHE II
score (range)
12 (2–37) 11 (0–30) 0.147
Median C-reactive
protein in mg/L (range)
185 (6–410) 155 (10–430) 0.733
Median albumin in g/L
(range)
31 (16–42) 30 (17–45) 0.978
Source of bacteraemiab
Low risk 8 (17.8) 30 (36.6) 0.027
Intermediate risk 11 (24.4) 39 (47.6) 0.011
High risk 26 (57.8) 13 (15.9) <0.001
Vancomycin Etest MIC
>1 mg/L
22 (48.9) 29 (35.4) 0.137
Vancomycin AUC0–24/
MICBMD <398
27 (60.0) 23 (28.0) 0.001
Vancomycin trough at
steady state <15 mg/L
21 (46.7) 26 (31.7) 0.095
ICU, intensive care unit; MIC, minimum inhibitory concentration; AUC, area under
the concentration curve; BMD, broth microdilution; IQR, interquartile range.
Values expressed as numbers (%) unless otherwise stated.
Low risk: line-related bacteraemia (n = 35) and other sources (n = 3).
Intermediate risk: bone and joint (n = 14), skin and soft tissue infections (n = 20),
deep abscess (n = 4), no identified focus (n = 12).
High risk: infective endocarditis (n = 12), pneumonia (n = 19), abdominal sources
(n = 6) and non-endocarditis vascular sources (n = 2).
aTreatment failure defined as one of the following: persistent bacteraemia,
microbiological failure or overall 30-day mortality (see text for details). Data
presented in numbers of cases (%) unless stated.
bSource of bacteraemia grouped into one of three groups based on overall
mortality risk (see text for details).
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observation is not entirely unexpected as microbiological
failure or persistent bacteraemia is commonly associated with
high inoculum infections such as infective endocarditis [3,27].
Nevertheless, failure still occurred with all bacteraemic
sources. Our data suggest that bacteraemic source or
infection-specific AUC0–24/MICBMD targets may exist.
Although these findings require confirmation prior to intro-
duction into clinical practice, we anticipate that AUC0–24/
MICBMD targets for low-risk sources secondary to skin and
soft tissue infections (SSTI) are lower than those required for
high-risk MRSA bacteraemic sources to achieve similar cure
rates.
It is clear from our study that optimized dosing in MRSA
bacteraemia requires monitoring of both AUC0–24 and MIC
values. Alternatively, it can be inferred from our data that
vancomycin trough monitoring may not be of benefit.
However, this is not the case, with trough monitoring still
the best indicator of possible nephrotoxicity [17]. Further-
more, original modelling data suggest that adequate phar-
macodynamic targets are obtained when dosing is based on
vancomycin trough concentrations provided MICs are
≤1 mg/L [8]. However, the level of accuracy with respect
to the true attained AUC0–24/MICBMD at an individual patient
level would be method dependent, with trough measure-
ments the least accurate, and Bayesian modelling based on
frequent sampling the most accurate. Which method should
be employed at the bedside is unclear and is likely to vary
with the clinical setting. For example, optimized therapy
based on AUC/MIC monitoring may be more appropriate in
critically ill patients, such as those in the intensive care unit,
compared with ward patients with uncomplicated bactera-
emia.
Clinicians should be cognizant, however, that the equation
used is dependent on creatinine clearance (CrCL) estimations,
which are likely to be an additional source of error. Unlike a
recent study [11], we found that the method of determining
CrCL did affect the AUC/MIC result, with the Modified Diet in
FIG. 2. Box plots for vancomycin AUC0–24/MICBMD values in patients
experiencing treatment failure or success stratified by source of MRSA
bacteraemia. Source of bacteraemia grouped into one of three groups
based on overall mortality risk (see text for details). Median and
interquartile AUC0–24/MICBMD values are represented by boxplots
with whiskers representing minimum and maximum values. Circles
represent outliers.
FIG. 3. The proportion of patients not
responding to vancomycin by source of
bacteraemia when AUC24/MICBMD values
were above and below CART-identified
source-specific targets. Source of
bacteraemia grouped into one of three
groups based on overall mortality risk (see
text for details).
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Renal Disease (MDRD) and the Cockcroft-Gault equations
yielding different results (data not shown). This may be due to
the fact that one (the Cockcroft-Gault equation) relies on
body weight, whereas the other (the MDRD equation) does
not; approximately 9% of patients weighed >100 kg in our
study. Clinicians should therefore consider which formula to
use in the context of their patient population. Notwithstanding
these additional complexities, AUC estimation methods pro-
vide a more accurate assessment of vancomycin exposure than
current dosing strategies dependant solely on vancomycin
trough levels [28].
Clinicians should also be mindful of the impact of MIC
results on the final AUC0–24/MIC. This is attributed to the
subtle differences between methodologies, with Etest generally
yielding MIC results approximately one to two dilutions higher
than BMD [29,30]. Similarly, inter-method differences exist
with automated susceptibility platforms (e.g. Vitek2), yielding
MIC results one to two dilutions lower than BMD [29,30].
These differences, although significant, can be easily circum-
vented by aiming for an appropriate MIC method-specific
AUC0–24/MIC target. This is not the case for automated
susceptibility platforms, which require validation and estab-
lishment of a comparable AUC0–24/MIC target before general
implementation.
There are several limitations to our study, including the
retrospective design. Our results require validation in patient
groups excluded from our study, such as paediatric patients or
patients receiving dialysis for chronic renal impairment. AUC
estimation formulae as employed in our study assume linear
vancomycin pharmacokinetics, stable renal clearance and
volume of distribution and as such may not be applicable in
morbidly obese or critically ill patients. As stored isolates were
used for MIC determination, this may have affected the
observed PK/PD targets. Other PK parameters, including
protein binding or the free drug fraction, were not examined in
this study [31].
In conclusion, vancomycin trough concentrations are
unlikely to accurately reflect AUC0–24/MIC targets and may
result in suboptimal outcomes. AUC estimation based on
validated formulae allow for individual patient dose optimiza-
tion, resulting in increased treatment success when a vanco-
mycin exposure or AUC0–24/MICBMD of ≥398 is achieved.
Furthermore, infection-specific targets may exist but require
further study and confirmation before implementation.
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